Table 3.

Summary of treatment-related AEs in the Japanese population

	Pembrolizumab (n = 23)	Pembrolizumab-chemotherapy (n = 25)	EXTREME (n = 19)
Any treatment-related AEsa	17 (73.9)	25 (100)	19 (100)
Grade 3–5	5 (21.7)	19 (76.0)	17 (89.5)
Serious	3 (13.0)	7 (28.0)	5 (26.3)
Death	0	1 (4.0)	0
Discontinuation due to treatment-related AEs	2 (8.7)	1 (4.0)	4 (21.1)
Discontinuation due to serious treatment-related AEs	2 (8.7)	1 (4.0)	2 (10.5)

Data are n (%). Non-serious AEs within 30 days of the last dose and serious AEs within 90 days of the last dose are included. ^aDetermined by the investigator to be related to study treatment

AE adverse event